secwatch.observer — SEC 8-K summary
======================================

Issuer:     EKSO BIONICS HOLDINGS, INC. (CHRN)
CIK:        0001549084
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0001437749-24-032290
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ekso Bionics Q3 rev $4.1M (-11% YoY), loss narrows; announces CMS reimbursement
-------------------------------------------------------------------------------

- Revenue $4.1M (Q3 2024) vs $4.6M (Q3 2023); 33 EksoHealth devices sold.
- Gross margin improved to 53.5% from 53.3% on supply chain cost savings.
- Net loss narrowed to $2.1M ($0.10/share) from $3.4M ($0.24/share) YoY.
- Received CMS reimbursement for Ekso Indego Personal, enabling Medicare coverage for SCI patients.
- Cash $8.3M at Sep 30, 2024; raised $5.0M net in underwritten offering during September.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549084/000143774924032290/0001437749-24-032290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549084/000143774924032290/ekso20241018_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-032290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer